KIR immune checkpoint inhibitors are cancer therapy drugs with targeting killer immunoglobulin-like receptors (KIRs), which are a family of cell surface proteins found on natural killer (NK) cells. They inhibit the killing function of these cells by interacting with MHC class I molecules. The MHC class I molecules are expressed on all cells, including tumour cells. The KIR immune checkpoint inhibitors can be used to treat cancer. Lirilumab is one of the KIR immune checkpoint inhibitors used to treat Leukemia and some solid tumours.
|Disease||KIR immune checkpoint inhibitors research developments|
|Leukemia||Lirilumab —— A phase II trial of lirilumab (KIR immune checkpoint inhibitors drug) combined with rituximab for relapsed, refractory or high-risk untreated patients with chronic lymphocytic (CLL) (NCT02481297).|
|others||Lirilumab (BMS-986015) —— a KIR immune checkpoint inhibitors drug, is being tested in combination with nivolumab, an anti-PD-1 antibody, in a phase I study for patients with advanced solid tumors (NCT01714739)|